Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 13/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27227885 | 1.00 | ULK1 (0.58) | ULK1LRRK2CYP1A2ULK2CHEK1 | |
| SCHEMBL30860894 | 0.90 | ULK1 (0.57) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL30860804 | 0.89 | FLT3 (0.59) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL27228222 | 0.89 | FLT3 (0.59) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL30861089 | 0.89 | ULK1 (0.56) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL30860789 | 0.88 | LRRK2 (0.54) | ULK1LRRK2CYP1A2ULK2CHEK1 | |
| SCHEMBL30860772 | 0.88 | LRRK2 (0.56) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL27227990 | 0.88 | LRRK2 (0.56) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL30860918 | 0.88 | ULK1 (0.56) | ULK1LRRK2ULK2CHEK1FLT3 | |
| SCHEMBL27228257 | 0.88 | ULK1 (0.56) | ULK1LRRK2ULK2CHEK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | ULK1 138/4885LRRK2 1/4885CYP1A2 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.